Affinity Asset Advisors’s Kezar Life Sciences KZR Stock Holding History

Affinity Asset Advisors’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-229,076	Closed	-$1.7M	–	123
2026 Q1	$1.7M	Hold	229,076	–	–	0.09%	96
2025 Q4	$1.44M	Buy	+229,076	New	+$1.34M	0.08%	84
2025 Q1	–	Sell	-142,316	Closed	-$956K	–	106
2024 Q4	$956K	Sell	142,316 -108,862	-43%	-$811K	0.13%	70
2024 Q3	$1.94M	Buy	251,178 +75,000	+43%	+$452K	0.27%	65
2024 Q2	$1.06M	Hold	176,178	–	–	0.12%	81
2024 Q1	$1.59M	Buy	+176,178	New	+$1.6M	0.2%	77

Affinity Asset Advisors's KZR Position: Q2 2026 in Review

Affinity Asset Advisors sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 229,076 shares — an estimated $1.7M sold.

Affinity Asset Advisors first reported a position in KZR in Q1 2024 and held it in 6 quarters. The position peaked at $1.94M in Q3 2024. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.

Affinity Asset Advisors reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
Affinity Asset Advisors sold 229,076 Kezar Life Sciences shares in Q2 2026, an estimated $1.7M.
Affinity Asset Advisors first reported a position in Kezar Life Sciences in Q1 2024 and held it in 6 quarters.
Affinity Asset Advisors's Kezar Life Sciences position peaked at $1.94M in Q3 2024.
0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.